REHILGO
Live / Registered — Registered (as of 31 Aug 2021)
What this means for you
Registered since 31 Aug 2021. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (the §71 affidavit of use is due by 31 Aug 2027, and its filing window is open now).
Record
- Serial number
- 79294261
- Registration number
- 6465745
- Mark type
- Word mark
- Filed
- 30 Jul 2020
- Published for opposition
- 15 Jun 2021
- Registered
- 31 Aug 2021
- Next maintenance filing
- §71 affidavit of use, due by 31 Aug 2027 (grace period to 29 Feb 2028)
- Attorney of record
- Scott D. Woldow
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza
Owner
- CSL Behring GmbH, DE
- CSL Behring GmbH, DE
- CSL Behring GmbH, DE
Board proceedings on this mark
The owner also pleads this mark in 1 other Board proceeding.
Prosecution history
- 31 Aug 2026 — COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
- 31 Aug 2026 — COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
- 04 Nov 2022 — NEW REPRESENTATIVE AT IB RECEIVED
- 27 Feb 2022 — FINAL DECISION TRANSACTION PROCESSED BY IB
- 07 Feb 2022 — FINAL DISPOSITION NOTICE SENT TO IB
- 07 Feb 2022 — FINAL DISPOSITION PROCESSED
- 30 Nov 2021 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
- 31 Aug 2021 — REGISTERED-PRINCIPAL REGISTER
- 15 Jun 2021 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 15 Jun 2021 — PUBLISHED FOR OPPOSITION
- 26 May 2021 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 12 May 2021 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 11 May 2021 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 11 May 2021 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 11 May 2021 — TEAS RESPONSE TO OFFICE ACTION RECEIVED